ING Group’s Myriad Genetics MYGN Stock Holding History

ING Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-6,510	Closed	-$251K	–	778
2014 Q3	$251K	Hold	6,510	–	–	﹤0.01%	621
2014 Q2	$253K	Sell	6,510 -80,104	-92%	-$2.98M	﹤0.01%	620
2014 Q1	$2.96M	Sell	86,614 -21,087	-20%	-$653K	0.02%	432
2013 Q4	$2.26M	Buy	+107,701	New	+$2.72M	0.01%	450

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ING Group's MYGN Position: Q4 2014 in Review

ING Group sold out of Myriad Genetics (MYGN) in Q4 2014, closing a stake of 6,510 shares — an estimated $251K sold.

ING Group first reported a position in MYGN in Q4 2013 and held it in 4 quarters. The position peaked at $2.96M in Q1 2014. 272 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

ING Group reported no remaining Myriad Genetics position as of Q4 2014 after selling out during the quarter.
ING Group sold 6,510 Myriad Genetics shares in Q4 2014, an estimated $251K.
ING Group first reported a position in Myriad Genetics in Q4 2013 and held it in 4 quarters.
ING Group's Myriad Genetics position peaked at $2.96M in Q1 2014.
272 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on ING Group's 13F filing for Q4 2014, filed 17 Feb 2015.